RELX Technology to Release Unaudited Q1 2024 Financial Report

Business by 2FIRSTS.ai

May.07.2024

RELX Technology to Release Unaudited Q1 2024 Financial Report

RELX Technology (RLX) to release unaudited Q1 2024 financial report on May 17, followed by earnings call.

On May 7th, according to RELX Technology (RLX Technology Inc) (NYSE: RLX) official website, the unaudited financial report for the first quarter of 2024 (ending on March 31, 2024) will be released before the opening on May 17th (Friday).

The company's management will hold a financial report conference call at 8:00 AM Eastern Time on May 17 to analyze the performance trends of the quarter.

References:

[1] RLX Technology to Report First Quarter 2024 Financial Results on May 17, 2024

Also Read:

[1] RELX 2023FY: Net Profit Decreased by 42.6% YoY to $130 Million, Increased by 73.2% in Q4

[2] RELX Releases Unaudited Financial Report for Q3 2023

#North America #United States #Technology.#RELX Technology #Major companies

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | VOZOL Launches Two SLEEK-Series Devices Compatible with Mesh and Ceramic Coils

VOZOL expands its SLEEK line with the SLEEK VISION e-cigarette, which uses the same series pods and supports both mesh and ceramic coils. SLEEK VISION features a boxier design with a 0.99-inch display for battery level and mode, and upgrades the battery to 900 mAh (vs. 600 mAh on SLEEK).

Nov.11 by 2FIRSTS.ai

Ukraine intensifies crackdown on illicit tobacco and alcohol markets

Ukraine’s State Tax Service (GNS) has carried out around 24,000 on-site inspections in the tobacco and alcohol sectors this year, imposing more than ₴795 million (US$194 million) in fines and revoking over 2,500 business licences.

Oct.17 by 2FIRSTS.ai

South Korea Implements Public Tobacco Harmfulness Management Program, Including 22 Harmful Components in E-Cigarettes

South Korea’s Ministry of Health and Welfare and the Ministry of Food and Drug Safety convened the first 2025 Tobacco Harmfulness Management Policy Committee, finalizing new lists of harmful substances for cigarettes, heated tobacco products, and liquid e-cigarettes to be publicly disclosed from next year.

Nov.14 by 2FIRSTS.ai

ceshi1111

Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st